Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

About this update from Phathom Pharmaceuticals, Inc.

[{"type":"image","alt":"Phathom Pharmaceuticals","displaySize":"","headline":null,"caption":"Phathom Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/08e599db31de5fdce3058dc9a47e4693"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6SL2C6WY7yKSFTq44iAahw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMg--/https://media.zenfs.com/en/globenewswire.com/08e599db31de5fdce3058dc9a47e4693","width":300,"height":87}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT","length":78,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":78,"olType":false},{"type":"text","content":"FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update.","length":398,"tagName":"p"},{"type":"text","content":"A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the call.","length":307,"tagName":"p"},{"type":"text","content":"About Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin ...

More updates from Phathom Pharmaceuticals, Inc.